Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
NCT00378521
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Raynaud's Disease
Raynaud's Disease Secondary to Scleroderma
Raynaud's Disease Secondary to Autoimmune Disease
Interventions
DRUG:
MQX-503
Sponsor
MediQuest Therapeutics